¼¼°èÀÇ »ýü ÀÓÇöõÆ® ½ÃÀå
Biological Implants
»óǰÄÚµå : 1758037
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 281 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,068,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,204,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »ýü ÀÓÇöõÆ® ½ÃÀåÀº 2030³â±îÁö 110¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 86¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ »ýü ÀÓÇöõÆ® ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 110¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ »ý¹°ÇÐÀû ÀÚ±â ÀÌ½ÄÆíÀº CAGR 3.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 63¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ý¹°ÇÐÀû µ¿Á¾ÀÌ½ÄÆí ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 23¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »ýü ÀÓÇöõÆ® ½ÃÀåÀº 2024³â¿¡ 23¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 21¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.0%¿Í 4.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ »ýü ÀÓÇöõÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»ýü ÀÓÇöõÆ®°¡ Àç»ýÀÇ·á¿Í ¼ö¼úÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

»ýü ÀÓÇöõÆ®´Â ´Ù¾çÇÑ ÀÓ»ó ¿ëµµ¿¡¼­ ÀÚ¿¬ Ä¡À¯, Á¶Á÷ ÅëÇÕ ¹× ±â´É ȸº¹À» ÃËÁøÇÏ´Â »ý¹°ÇÐÀûÀ¸·Î ÀûÇÕÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á Çö´ë ÀÇÇп¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. »ýü ÀÓÇöõÆ®´Â ±Ý¼ÓÀ̳ª ÇÃ¶ó½ºÆ½À¸·Î ¸¸µç ÇÕ¼º ÀÓÇöõÆ®¿Í ´Þ¸® Àΰ£(ÀÚ°¡ ¶Ç´Â µ¿Á¾ ÀÌ½ÄÆí) ¶Ç´Â µ¿¹°(ÀÌÁ¾ ÀÌ½ÄÆí)ÀÇ Ãµ¿¬ Á¶Á÷À¸·Î ¸¸µé¾îÁö¸ç, Áß¿äÇÑ »ý¹°ÇÐÀû ±¸Á¶¸¦ À¯ÁöÇϸ鼭 »ýü ÀûÇÕ¼º°ú ¹«±Õ¼ºÀ» º¸ÀåÇϵµ·Ï °¡°øµË´Ï´Ù. ÀÌ·¯ÇÑ ÀÓÇöõÆ®´Â ¼¼Æ÷ Áõ½ÄÀ» ÃËÁøÇϰí, ¸é¿ª °ÅºÎ¹ÝÀÀÀ» ¾ïÁ¦Çϸç, Ä¡À¯ ¼ºÀûÀ» Çâ»ó½ÃŰ´Â ´É·ÂÀÌ ÀÖÀ¸¸ç, Á¤Çü¿Ü°ú, ½ÉÇ÷°ü¿Ü°ú, Ä¡°ú, ¾È°ú, Àç°Ç¿Ü°ú µî¿¡¼­ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ëÈ­¿¡ µû¸¥ ÅðÇ༺ Áúȯ, ¿Ü»ó, °üÀý ġȯ¼ú ¹× Àå±â Àç°Ç¼ú°ú °°Àº ¿Ü°úÀû ½Ã¼úÀÌ Àü ¼¼°è¿¡¼­ Áõ°¡Çϰí ÀÖ´Â °Íµµ ±× º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Á¤Çü¿Ü°ú¼ö¼ú¿¡¼­ »ý¹°ÇÐÀû ¹ßÆÇÀ̳ª ÀÌ½ÄÆíÀº ¼Õ»óµÈ Àδë, ÈûÁÙ, ¿¬°ñÀ» ´ëüÇϰųª º¸°­ÇÏ¿© º¸´Ù ÀÚ¿¬½º·¯¿î ȸº¹ °æ·Î¿Í ÇÕº´Áõ °¨¼Ò¸¦ ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ½ÉÇ÷°ü ¼ö¼ú¿¡¼­ »ý¹°ÇÐÀû ½ÉÀå ÆÇ¸·Àº Ç÷Àü ¹ß»ý À§ÇèÀÌ ³·°í, Æò»ý Ç×ÀÀ°í ¿ä¹ýÀÌ ´ú ÇÊ¿äÇϹǷΠ±â°èÀû ´ëüǰº¸´Ù »ý¹°ÇÐÀû ½ÉÀå ÆÇ¸·ÀÌ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÃÖ¼Ò Ä§½ÀÀû ¼ö¼ú, ªÀº ȸº¹ ½Ã°£, ³·Àº Àå±â À̹°Áú ¹ÝÀÀ ¹ß»ý·ü µî ȯÀÚµéÀÇ ¼±È£µµ¿¡ µû¶ó »ý¹°ÇÐÀû ÀÓÇöõÆ®¿¡ ´ëÇÑ ¼ö¿ä´Â ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇコÄɾ Àç»ý ¹× ¸ÂÃãÇü ÀÇ·á·Î ÀüȯÇÏ´Â °¡¿îµ¥, »ýü ÀÓÇöõÆ®´Â ¿Ü°úÀû Çõ½ÅÀÇ ÃÖÀü¼±¿¡ ¼­¼­ ÀÓ»óÀǰ¡ Ä¡À¯¿Í ±¸Á¶Àû ¼öº¹¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº »ýü ÀÓÇöõÆ®ÀÇ ¼º´É°ú ½Å·Ú¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

Á¶Á÷°øÇÐ, Àç·á°úÇÐ, ¹ÙÀÌ¿À¸ÞµðÄà ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î »ýü ÀÓÇöõÆ®ÀÇ ¼º´É°ú ½Å·Ú¼ºÀÌ ´«¿¡ ¶ç°Ô Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Å»¼¼Æ÷È­ ±â¼úÀº ¼÷ÁÖ Á¶Á÷ÀÇ ÅëÇÕÀ» Áö¿øÇÏ´Â ¼¼Æ÷¿Ü ¸ÅÆ®¸¯½º¸¦ À¯ÁöÇϸ鼭 °ø¿©ÀÚÀÇ ¼¼Æ÷ ³»¿ëÀ» Á¦°ÅÇÒ ¼ö ÀÖµµ·Ï ´õ¿í Á¤¹ÐÇØÁ³½À´Ï´Ù. ÀÌ ±â¼ú Çõ½ÅÀº ³»ÇÏÁß ¹× ±¸Á¶Àû Àû¿ë¿¡ ÇÊ¿äÇÑ ±â°èÀû ¹«°á¼ºÀ» À¯ÁöÇϸ鼭 ¸é¿ª¿ø¼ºÀ» Å©°Ô °¨¼Ò½Ãŵ´Ï´Ù. ¶ÇÇÑ °¨¸¶¼± Á¶»ç, ÃÊÀÓ°è CO2, ¿¡Æ¿·»¿Á»çÀÌµå µîÀÇ ¸ê±Õ ¹æ¹ýÀ» °³¼±ÇÏ¿© Á¶Á÷ÀÇ Æ¯¼ºÀ» ÀúÇϽÃŰÁö ¾ÊÀ¸¸é¼­µµ ¾ÈÀü¼ºÀ» º¸ÀåÇϸç, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃÀ» Æ÷ÇÔÇÑ ¹ÙÀÌ¿ÀÆÐºê¸®ÄÉÀÌ¼Ç ±â¼úÀ» ÅëÇØ ȯÀÚÀÇ ÇØºÎÇÐÀû ±¸Á¶¿Í Ä¡À¯ ¿ä°Ç¿¡ ¸Â´Â ¼¼Æ÷¿Í ¼ºÀåÀÎÀÚ¸¦ À̽ÄÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ½Ä °¡´ÉÇÑ ¸ÂÃãÇü ½ºÄ³Æúµå¸¦ Á¦ÀÛÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ³ª³ë ±â¼úµµ ÀÌ·¯ÇÑ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ³ª³ë ±¸Á¶ ÄÚÆÃ°ú ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» »ýü³» ÀÓÇöõÆ®¿¡ ÅëÇÕÇÏ¿© Ç×»ýÁ¦, Ç׿°Áõ¾à, Àç»ý È­ÇÕ¹°À» ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¹æÃâÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸ÀÚµéÀº õ¿¬ Á¶Á÷°ú »ýüÈí¼ö¼º Æú¸®¸Ó¸¦ °áÇÕÇÏ¿© ±¸Á¶Àû °­µµ¸¦ ³ôÀÌ°í ºÐÇØ ¼Óµµ¸¦ Á¶ÀýÇÏ´Â º¹ÇÕ »ýü ÀÓÇöõÆ®¸¦ °³¹ßÇϰí ÀÖÀ¸¸ç, MRI ¹× CT¿Í °°Àº ¿µ»ó ±â¼úÀÇ Çâ»óÀ¸·Î ¼ö¼ú Àü °èȹÀÌ ¿ëÀÌÇØÁö°í, ÀÓÇöõÆ®¿Í ¼÷ÁÖ Á¶Á÷°úÀÇ ¸ÅĪÀÌ °³¼±µÇ¾î ¼ö¼ú °á°ú°¡ Çâ»óµÇ°í, ¼ö¼ú ÈÄ ÇÕº´ÁõÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ÈÄ ÇÕº´ÁõÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ Åø°ú ¿þ¾î·¯ºíÀÌ ÀÓÇöõÆ®¿Í °áÇÕÇÏ¿© ÅëÇÕ°ú Ä¡À¯¸¦ ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÏ´Â ½º¸¶Æ® ÀÓÇöõÆ® ½Ã½ºÅÛÀÇ ½Ã´ë°¡ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº »ýü ÀÓÇöõÆ®ÀÇ Ç°Áú°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó º¹ÀâÇÑ ÀÇ·á ¹®Á¦¿¡ ´ëÇÑ Àû¿ë ¹üÀ§¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû ÀÓÇöõÆ® äÅÃÀÌ ±ÞÁõÇϰí ÀÖ´Â ÀÇ·á ºÐ¾ß¿Í ¼¼°è Áö¿ªÀº?

Á¶Á÷ º¹±¸¿Í »ýü ÀûÇÕ¼ºÀÌ °¡Àå Áß¿äÇÑ ¿©·¯ ÀÇ·á ºÐ¾ß¿¡¼­ »ýü ÀÓÇöõÆ® äÅÃÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. Á¤Çü¿Ü°ú´Â ¿©ÀüÈ÷ Áö¹èÀûÀÎ ºÐ¾ß·Î ¹Ý¿ù»ó ¿¬°ñÆÇ ÀÌ½ÄÆí, °ñÀÌ½ÄÆí, ÈûÁÙ ºñ°è¿Í °°Àº ÀÓÇöõÆ®°¡ ½ºÆ÷Ã÷ ¿Ü»ó, °ñÀý, ÅðÇ༺ ÁúȯÀÇ ¼öº¹¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÀÇ·áµµ ÁÖ¿ä °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ƯÈ÷ Àΰø½ÉÀåÆÇ¸·, Ç÷°ü ÆÐÄ¡, ½É¸· Á¶Á÷Àº ÆÇ¸·ÀÇ ¼öº¹°ú ¼±ÃµÀû °áÇÔÀÇ ±³Á¤¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Àç°Ç ¹× ¼ºÇü¿Ü°ú¿¡¼­´Â ¿Ü»ó, È­»ó, ¼ºÇü ¼ö¼ú ÈÄ Á¶Á÷ Àç»ýÀ» Áö¿øÇϱâ À§ÇØ ÁøÇÇ ¸ÅÆ®¸¯½º ¹× Äݶó°Õ ½ºÄ³Æúµå¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Ä¡°ú¿¡¼­´Â Ä¡ÁÖÁúȯÀÇ ¼öº¹°ú ÀÓÇöõÆ® °íÁ¤¿¡ »ýü¸·°ú »À ´ëü¹°ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾È°ú¿Í ½Å°æ¿Ü°ú¿¡¼­µµ °ÅºÎ¹ÝÀÀÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϸ鼭 °æ¸·°ú ¾È±¸ Á¶Á÷À» º¹±¸Çϱâ À§ÇØ »ý¹°ÇÐÀû Àç·á¸¦ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ³ôÀº ÀÇ·áºñ ÁöÃâ, ÷´ÜÈ­µÈ ¼ö¼ú ÀÎÇÁ¶ó, À¯¸®ÇÑ »óȯÁ¦µµ·Î ÀÎÇØ ¼¼°è ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº źźÇÑ ÀÌ½Ä ³×Æ®¿öÅ©¿Í ¾ÈÀü°ú Çõ½ÅÀ» º¸ÀåÇÏ´Â °­·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. À¯·´Àº Àç»ýÀÇ·á¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø°ú ÁÖ¿ä ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÇ Á¸Àç·Î ÀÎÇØ ±Ù¼ÒÇÑ Â÷ÀÌ·Î µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ, ÀϺ»°ú °°Àº ±¹°¡ÀÇ ÀÇ·á ÅõÀÚ Áõ°¡, ÀÎÁöµµ Çâ»ó, ´ë±Ô¸ð ȯÀÚ ±â¹Ý¿¡ ÈûÀÔ¾î °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀÔ´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿Àº ÀÇ·á Á¢±Ù¼º Çâ»ó°ú ÀÇ·á °ü±¤ÀÇ ºÎ»óÀ¸·Î ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï Áö¿ªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ´Ù¾çÇÑ Áö¿ª¿¡¼­ ȯÀÚ Áß½ÉÀûÀ̰í Á¶Á÷ ÀûÇÕ¼ºÀÌ ³ôÀº ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó »ýü ÀÓÇöõÆ®°¡ ±âÁ¸ ÇÕ¼º Á¦Ç°º¸´Ù ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼¼°è »ýü ÀÓÇöõÆ® ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

¼¼°è »ýü ÀÓÇöõÆ® ½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á, ±â¼ú, Àα¸ Åë°è, Á¤Ã¥ µî ´Ù°¢ÀûÀÎ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ´ëÇ¥ÀûÀÎ °ÍÀÌ °ñ°üÀý¿°, ½ÉÇ÷°ü Áúȯ, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ Àü ¼¼°è Àα¸ÀÇ ºÎ´ã Áõ°¡·Î ÀÓÇöõÆ®¸¦ ÀÌ¿ëÇÑ ¿Ü°úÀû °³ÀÔÀÌ ºó¹øÇÏ°Ô ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¼±Áø±¹ ¹× ÁßÁø±¹¿¡¼­´Â °í·ÉÈ­°¡ ÁøÇàµÇ°í ÀÖÀ¸¸ç, °í·É ȯÀÚ´Â Àΰø°üÀý ġȯ¼ú, ÆÇ¸·Áõ ¼ö¼ú, Á¶Á÷ Àç°Ç¼úÀ» ¹ÞÀ» °¡´É¼ºÀÌ ³ô±â ¶§¹®¿¡ ÀÌ ¶ÇÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½ÀÀû Ä¡·á ¹× Àç»ý Ä¡·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ÀÓ»óÀǵéÀº ¼ö¼úÀû ¿Ü»ó°ú ȸº¹ ½Ã°£À» ÁÙÀ̰í ÀÚ¿¬ Ä¡À¯¸¦ ÃËÁøÇÏ´Â »ý¹°ÇÐÀû ÀûÇÕ¼ºÀÌ ³ôÀº ÀÓÇöõÆ®¸¦ ¼±ÅÃÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¹ÙÀÌ¿À ¿£Áö´Ï¾î¸µ, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ, ¼¼Æ÷ Ä¡·á¿Í °°Àº ±â¼ú Çõ½ÅÀº ÀÌ½Ä °¡´ÉÇÑ »ý¹°ÇÐÀû ¹°ÁúÀÇ ¹üÀ§¿Í È¿´ÉÀ» È®´ëÇϰí ÀÖÀ¸¸ç, FDA ¹× EMA¿Í °°Àº ±ÔÁ¦±â°üÀº ¹ÌÃæÁ·µÈ ÀÓ»óÀû Çʿ並 ÃæÁ·½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» ÀνÄÇÏ°í »ý¹°Á¦Á¦ÀÇ ½ÂÀÎ °æ·Î¸¦ °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. º¸Çè Àû¿ë ¹× »óȯ ¸ðµ¨µµ ÀÌ·¯ÇÑ »õ·Î¿î ¼Ö·ç¼Ç¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ÁøÈ­Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ÀÓ»óÀû Áõ°Å¸¦ ÅëÇØ Àå±âÀûÀÎ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ Áö¼ÓÀûÀ¸·Î °ËÁõµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Çаè, ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷ ¹× ±âÁ¸ ÀÇ·á ±â¼ú ±â¾÷ °£ÀÇ Çù·Â °­È­·Î ¿¬±¸, »ó¾÷È­ ¹× ¼¼°è À¯ÅëÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇÕ¼º ÀÓÇöõÆ®¸¦ µÑ·¯½Ñ ȯ°æ ¹× À±¸®Àû ¹®Á¦µµ »ýºÐÇØ¼º ¹× »ý¹°ÇÐÀû ´ëüǰÀ¸·ÎÀÇ ÀüȯÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© »ýü ÀÓÇöõÆ®´Â Â÷¼¼´ë ÀÇ·áÀÇ ÇÙ½É ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, ±â´É ȸº¹ÀÌ ´Ü¼øÈ÷ ´ëü¸¦ ÅëÇØ°¡ ¾Æ´Ï¶ó ÁøÁ¤ÇÑ »ý¹°ÇÐÀû ÅëÇÕ°ú Àç»ýÀ» ÅëÇØ ÀÌ·ç¾îÁú ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(»ý¹°ÇÐÀû ÀÚ°¡ ÀÌ½ÄÆí, »ý¹°ÇÐÀû µ¿Á¾ÀÌ½ÄÆí, »ý¹°ÇÐÀû ÀÌÁ¾ ÀÌ½ÄÆí); ¿ëµµ(½ÉÀåÇ÷°ü ÀÓÇöõÆ® ¿ëµµ, Á¤Çü¿Ü°ú ÀÓÇöõÆ® ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 44»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Biological Implants Market to Reach US$11.0 Billion by 2030

The global market for Biological Implants estimated at US$8.6 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Biological Autografts, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Biological Allografts segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 6.6% CAGR

The Biological Implants market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Biological Implants Market - Key Trends & Drivers Summarized

Why Are Biological Implants Reshaping the Future of Regenerative Medicine and Surgical Interventions?

Biological implants are revolutionizing modern medicine by providing biologically compatible solutions that facilitate natural healing, tissue integration, and functional restoration in a variety of clinical applications. Unlike synthetic implants made from metals or plastics, biological implants are derived from natural tissues-either human (autografts or allografts) or animal (xenografts)-that are processed to ensure biocompatibility and sterility while retaining essential biological structures. These implants are increasingly used in orthopedic, cardiovascular, dental, ophthalmic, and reconstructive surgeries due to their ability to promote cellular growth, reduce immune rejection, and improve healing outcomes. Their widespread adoption is also being driven by the global increase in age-related degenerative diseases, trauma-related injuries, and surgical interventions such as joint replacements and organ reconstructions. For example, in orthopedic procedures, biological scaffolds and grafts are replacing or augmenting damaged ligaments, tendons, and cartilage with more natural recovery paths and fewer complications. Similarly, in cardiovascular surgery, biological heart valves are favored over mechanical alternatives for their lower thrombogenic risk and reduced need for lifelong anticoagulation therapy. The demand for biologically derived implants is further amplified by patient preference for minimally invasive procedures, faster recovery times, and lower incidences of long-term foreign body reactions. As healthcare shifts towards regenerative and personalized medicine, biological implants stand at the forefront of surgical innovation-transforming the way clinicians approach healing and structural repair.

How Are Technological Innovations Enhancing the Performance and Reliability of Biological Implants?

The performance and reliability of biological implants have been significantly improved by ongoing advancements in tissue engineering, material science, and biomedical technologies. Decellularization techniques have become more precise, allowing the removal of donor cellular content while preserving the extracellular matrix that supports host tissue integration. This innovation greatly reduces immunogenicity while maintaining the mechanical integrity necessary for load-bearing or structural applications. Furthermore, sterilization methods using gamma irradiation, supercritical CO2, and ethylene oxide are now refined to ensure safety without degrading tissue properties. Biofabrication technologies, including 3D bioprinting, have enabled the creation of customized implantable scaffolds embedded with cells and growth factors tailored to the patient’s anatomy and healing requirements. Nanotechnology is also contributing to this progress, with nanostructured coatings and drug delivery systems being integrated into biological implants to release antibiotics, anti-inflammatory agents, or regenerative compounds over time. Additionally, researchers are developing composite biological implants that combine natural tissues with bioresorbable polymers to enhance structural strength and tailor degradation rates. Improvements in imaging technologies like MRI and CT have facilitated preoperative planning and better matching of implants with host tissue, improving surgical outcomes and reducing postoperative complications. Digital health tools and wearables are starting to be paired with implants to monitor integration and healing in real time, marking the beginning of smart implant systems. Together, these technological advancements are not only improving the quality and safety of biological implants but are also broadening their applicability across complex medical challenges.

Which Medical Fields and Global Regions Are Leading the Surge in Biological Implant Adoption?

The adoption of biological implants is surging across multiple medical fields where tissue restoration and biocompatibility are paramount. Orthopedics remains a dominant sector, where implants like meniscal allografts, bone grafts, and tendon scaffolds are used to repair sports injuries, fractures, and degenerative conditions. Cardiovascular medicine is another major driver, particularly in the use of bioprosthetic heart valves, vascular patches, and pericardial tissues for valve repair and congenital defect correction. Reconstructive and plastic surgery heavily relies on dermal matrices and collagen scaffolds to support tissue regeneration following trauma, burns, or cosmetic enhancements. In dental surgery, biological membranes and bone substitutes are used for periodontal repairs and implant anchoring. Ophthalmology and neurosurgery are also integrating biologically based materials to repair dura mater or ocular tissues with minimal rejection risk. Regionally, North America leads the global market due to high healthcare expenditure, advanced surgical infrastructure, and favorable reimbursement systems. The United States, in particular, benefits from a robust transplant network and strong regulatory frameworks that ensure safety and innovation. Europe follows closely, driven by government support for regenerative medicine and the presence of leading biotech firms. Asia-Pacific is the fastest-growing market, fueled by rising healthcare investments, increasing awareness, and a large patient base in countries like China, India, and Japan. Latin America and the Middle East are emerging regions where improvements in healthcare access and the rise of medical tourism are boosting demand. Across these varied geographies, the increasing focus on patient-centric, tissue-compatible solutions is making biological implants a preferred choice over traditional synthetic options.

What Is Fueling the Growth in the Global Biological Implants Market?

The growth in the global biological implants market is driven by a multifaceted combination of medical, technological, demographic, and policy-related factors that are collectively reshaping surgical care. Foremost among these is the rising global burden of chronic diseases, such as osteoarthritis, cardiovascular disorders, and diabetes, which frequently necessitate implant-based surgical interventions. The growing aging population, particularly in developed and middle-income countries, also contributes to increased demand, as elderly patients are more likely to undergo joint replacements, valve surgeries, and tissue reconstruction procedures. Moreover, the trend toward minimally invasive and regenerative treatments is pushing clinicians to choose biologically compatible implants that promote natural healing while reducing surgical trauma and recovery times. Technological innovation, including advancements in bioengineering, 3D bioprinting, and cellular therapies, is expanding the range and effectiveness of implantable biological materials. Regulatory bodies such as the FDA and EMA are streamlining approval pathways for biologics, recognizing their potential to address unmet clinical needs. Insurance coverage and reimbursement models are also evolving to accommodate these newer solutions, particularly as clinical evidence continues to validate their long-term safety and efficacy. Furthermore, increasing collaboration between academic institutions, biotech startups, and established medtech companies is accelerating research, commercialization, and global distribution. Environmental and ethical concerns around synthetic implants are also prompting a shift toward biodegradable and biologically derived alternatives. Collectively, these drivers are positioning biological implants as a critical component of next-generation medical care, where restoration of function is achieved not through replacement alone, but through true biological integration and regeneration.

SCOPE OF STUDY:

The report analyzes the Biological Implants market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Biological Autografts, Biological Allografts, Biological Xenografts); Application (Cardiovascular Implants Application, Orthopedic Implants Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â